California's historic Proposition 71 provided big money for stem-cell research after voters approved it eight years ago. The measure helped fund major advances, but some charge that the success has been hampered by cronyism and conflict of interest. Roman Reed has been a paraplegic for more than eighteen years. Ever since a college football injury injured his spine. Reed says he's confident he will walk again. "Stem cells are going to get me out of this chair. I will walk again one day because of stem cell research," said Reed. He campaigned hard for Prop 71 eight years ago. Voters believed stem cells might help find cures for paralysis, heart disease, diabetes and more. The proposition won and the California Institute for Regenerative Medicine or CIRM received $3 billion from taxpayers. The bond money was intended to find stem cell cures. Some are starting to question whether they have found any. "We do not have any cures, nor did we expect to have any cures within the time frame that we've funded so far," said CIRM's Chairman Jonathon Thomas. They have spent $1.7 billion dollars to date. The money has been used to build a dozen new laboratories. It has … Continue reading →

UPDATE on Stem Cell Therapy 7 November 2012 The Department of Health (DOH) saw the necessity to cover regulations for Stem Cell therapy. Stem Cell therapy belongs to the category of Advanced Cell therapy which includes biologics and blood. Many countries around the world apply a risk-based approach to assess the quality, efficacy and safety of advanced cell therapy. In many countries, Stem Cell is considered an investigational intervention. Stem Cell research employs both autologous (from same person) or allogenic (from another organism like animal or another human cell or tissue sample) method. Because there are many steps in the preparation of this lab and invasive procedure, there is therefore need to have a regulatory framework to protect Filipino citizens. Important questions were asked: is there proof of concept in animal trials where stem cell can then be applied in humans? Is there a way to ensure quality and purity of the raw materials? How safe is the procedure? How many did not benefit from the procedure? If this were investigational procedure, how will human subjects be protected? Sec. Enrique Ona convened a consultative working task force to provide recommendations on how to proceed in the early part of the … Continue reading →

Public release date: 8-Nov-2012 [ | E-mail | Share ] Contact: Jane Finlayson jane.finlayson@uhn.ca 416-946-2846 Princess Margaret Hospital (TORONTO, Canada Nov. 8, 2012) Canadian and Italian stem cell researchers have discovered a new "master control gene" for human blood stem cells and found that manipulating its levels could potentially create a way to expand these cells for clinical use. The findings, published today online ahead of print in Cell Stem Cell, usher in a new paradigm for the regulation of human blood stem cells, says co-principal investigator Dr. John Dick, who holds a Canada Research Chair in Stem Cell Biology and is a Senior Scientist at University Health Network's McEwen Centre for Regenerative Medicine and Ontario Cancer Institute (OCI), the research arm of the Princess Margaret Cancer Centre. He is also a Professor in the Department of Molecular Genetics, University of Toronto. "For the first time in human blood stem cells, we have established that a new class of non-coding RNA called miRNA represents a new tactic for manipulating these cells, which opens the door to expanding them for therapeutic uses," says Dr. Dick. In 2011, Dr. Dick isolated a human blood stem cell in its purest form as a … Continue reading →

NEW YORK, NY--(Marketwire - Nov 8, 2012) - Stem cell stocks have been gaining popularity among investors in 2012 as new and promising research continues to propel the industry forward. A study performed earlier this year at Johns Hopkins University has shown that stem cells from patients' own cardiac tissue can be used to heal scarred tissue after a heart attack. Five Star Equities examines the outlook for companies in the Biotechnology Industry and provides equity research on StemCells, Inc. ( NASDAQ : STEM ) and Neuralstem, Inc. ( NYSE : CUR ). Access to the full company reports can be found at: http://www.FiveStarEquities.com/STEM http://www.FiveStarEquities.com/CUR A more recent study, also conducted at Johns Hopkins University, has showed that stem cells donated by strangers were as safe and as effective as the patient's own cells in repairing heart tissue. This is a key advancement for the treatment of heart attack with stem cells, as this possibly means stem cells could be stored for use just as blood is now. "You could have the cells ready to go in the blood bank so when the patient comes in for a therapy -- there's no delay," said Dr. Joshua Hare of the University … Continue reading →

NEW YORK, NY--(Marketwire - Nov 8, 2012) - Stem cell stocks have been gaining popularity among investors in 2012 as new and promising research continues to propel the industry forward. A study performed earlier this year at Johns Hopkins University has shown that stem cells from patients' own cardiac tissue can be used to heal scarred tissue after a heart attack. Five Star Equities examines the outlook for companies in the Biotechnology Industry and provides equity research on Aastrom Biosciences, Inc. ( NASDAQ : ASTM ) and Neostem Inc. ( NYSE : NBS ). Access to the full company reports can be found at: http://www.FiveStarEquities.com/ASTM http://www.FiveStarEquities.com/NBS A more recent study, also conducted at Johns Hopkins University, has showed that stem cells donated by strangers were as safe and as effective as the patient's own cells in repairing heart tissue. This is a key advancement for the treatment of heart attack with stem cells, as this possibly means stem cells could be stored for use just as blood is now. "You could have the cells ready to go in the blood bank so when the patient comes in for a therapy -- there's no delay," said Dr. Joshua Hare of the … Continue reading →

Washington, November 8 (ANI): Administering to patients stem cells derived from their own bone marrow either three or seven days after a heart attack is safe but does not improve heart function six months later, according to a clinical trial. The results of the trial, called Transplantation In Myocardial Infarction Evaluation (TIME), mirror a previous, related study, LateTIME, which found that such cells (called autologous stem cells) given two to three weeks after a heart attack did not improve heart function. Both TIME and LateTIME were conducted by the Cardiovascular Cell Therapy Research Network (CCTRN), sponsored by the NIH's National Heart, Lung, and Blood Institute. "This study was extremely valuable even though it did not provide a demonstrated health benefit after six months," said Sonia Skarlatos, Ph.D., deputy director of NHLBI's Division of Cardiovascular Sciences and member of the CCTRN. "Heart stem cell therapy research is still in its infancy, and results from early trials have varied greatly due to differences in the numbers of stem cells injected, the delivery methods used, and the compositions of the study populations. With TIME and LateTIME, we have established both safety and baseline results in two large studies that followed the same procedures … Continue reading →

April Flowers for redOrbit.com Your Universe Online Conflicting studies were highlighted at this years American Heart Association Scientific Sessions meeting concerning stem cell therapy for heart attack patients. The first study, from the University of Louisville and Brigham and Womens Hospital, reported holy grail results for a Phase I clinical trial: marked sustained improvement in all patients with zero adverse effects. Roberto Bolli, M.D., of the University of Louisville and Piero Anversa, M.D., of Brigham and Womens Hospital presented data from their groundbreaking research in the use of autologous adult stem cells with patients who had previous heart attacks in a Late-Breaking Clinical Trial session. The researchers report that all patients receiving the stem cell therapy showed improved heart function after two years, with an overall 12.9 absolute unit increase in left ventricular ejection fraction (LVEF). LVEF is a standard measure of heart function that shows the amount of blood ejected from the left ventricle during a heartbeat. They saw no adverse effects from the therapy. In fact, nine patients showed evidence of myocardial regeneration new tissue replacing formerly dead tissue killed by heart attack in MRI scans. The trial shows the feasibility of isolating and expanding autologous stem cells … Continue reading →

UQ's Dr Amir Popat is a Young Nanoscience Ambassador and will visit schools next year to promote science and research. The University of Queensland's Australian Institute for Bioengineering and Nanotechnology (AIBN) researcher is keen to make science accessible to all people, starting with high school students in regional Queensland. Dr Popat will visit schools next year as part of an outreach program from the Australian Nanotechnology Network, with a school in Morayfield already lined up. As a Young Nanoscience Ambassador, he will talk about science as a rewarding career and present simple experiments to show the relevance of research in everyday lives. There are not a lot of schools outside the metropolitan area that have the opportunity to engage with scientists and be in touch with cutting-edge technology, especially nanotechnology, Dr Popat said. I want to promote science and higher education to students. It is important for the students to know that they can become researchers and come to AIBN. Students may not think of research as an employment area, but it is satisfying work and it helps society. The technology we are developing is not pie in the sky. There are things already in everyday use, such as tennis … Continue reading →

Dove Medical Press is blogging to keep readers up to date on journal activity for over 125 journals (PRWEB) November 07, 2012 "With over 125 journals publishing 10,000+ articles, we do not expect a shortage of interesting reading. The entries will consist of timely developments in a collection of fields, including science, technology and medicine. We are excited about this new development," writes Tim Hill, publisher, Dove Medical Press. The company goal is to give journal Editors-in-Chief avenue to inform their authors and readers about industry goings-on, as well as to provide them a chance to interact with each other. Including blog entries from the publisher and other key staff, Dove is confident that their newest endeavour will be of interest to readers and help to create some robust discussion. The first entries were created by Professor Thomas Webster and Dr. Richard Walker. Dr. Walker discusses sarcopenia and its significance in longevity medicine, while Professor Webster addresses a common question: Has the field of nanomedicine matured? Dove Medical Press is a privately held company specializing in the publication of Open Access peer-reviewed journals across the broad spectrum of science, technology and especially medicine. Meagan Wairama Dove Medical Press +64-9-476 6466 … Continue reading →

PURTIER Live Stem Cell Therapy - 4th Edition (English Version).mp4 PURTIER Live Stem Cell Therapy - 4th Edition (English Version) Please contact Pearly @ +65 9338 9541 for more detailsFrom:PurtierPearlyViews:3 0ratingsTime:09:00More inPeople Blogs Visit link: PURTIER Live Stem Cell Therapy - 4th Edition (English Version).mp4 - Video … Continue reading →